Diazoxide Choline Extended-release Tablets in Prader-Willi Syndrome: A Randomized, Double-blind, Withdrawal Period Study

20252 citationsJournal Articlehybrid Open Access

Authors

Jennifer Miller · University of Florida

Nicola Bridges · Chelsea and Westminster Hospital

Eric I. Felner · Emory University

Parisa Salehi · Seattle Children's Hospital

J. Yanovski · Eunice Kennedy Shriver National Institute of Child Health and Human Development

David A Stevenson · Palo Alto University

Jorge Mejia-Corletto

Abstract

Continued DCCR treatment was superior to placebo for hyperphagia. DCCR appears to offer meaningful therapeutic benefits for people with Prader-Willi syndrome.

Topics & Keywords

Genetic Syndromes and Imprinting Autophagy in Disease and Therapy Hedgehog Signaling Pathway Studies

Publication Details

Published in: The Journal of Clinical Endocrinology & Metabolism

DOI: 10.1210/clinem/dgaf661

Field-Weighted Citation Impact: 3.55

Command Palette

Diazoxide Choline Extended-release Tablets in Prader-Willi Syndrome: A Randomized, Double-blind, Withdrawal Period Study

Authors

Abstract

Topics & Keywords

Publication Details